Strizki JM, Tremblay C, Xu S, et al. 2005. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeﬁciency virus type 1. Antimicrob Agents Chemother, 49:4911–9. Takashima K, Miyake H, Kanzaki N, et al. 2005. Highly potent inhibition of human immunodeﬁciency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist. Antimicrob Agents Chemother, 49:3474–82. Thio CL, Astemborski J, Bashirova A, et al. 2007. Genetic protection against hepatitis B virus conferred by CCR5Delta32: Evidence that CCR5 contributes to viral persistence. J Virol, 81:441–5. Tsamis F, Gavrilov S, Kajumo F, et al. 2003. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeﬁciency virus type 1 entry. J Virol, 77:5201–8. Tsibris AMN, Gulick RM, Su Z, et al. 2007. In vivo emergence of HIV-1 resistance to the CCR5 antagonist vicriviroc: ﬁndings from ACTG A5211. Program and abstracts of the 16th International HIV Drug Resistance Workshop, Barbados, West Indies, Abstract 13. Unutmaz D, KewalRamani VN, Littman DR. 1998. G protein-coupled recep- tors in HIV and SIV entry: new perspectives on lentivirus-host interac- tions an on the utility of animal models. Semin Immunol, 10:225–36. van der Ryst E, Westby M. 2007. Changes in HIV-1 co-receptor tropism for patients participating in the maraviroc Motivate 1 and 2 clinical trials. Program and abstracts of the 47th Interscience Conference on Antimi- crobial Agents and Chemotherapy, Chicago, IL, Abstract H–715. CCR5 antagonists of HIV-1 infection Walensky RP, Paltiel AD, Losina E, et al. 2006. The survival beneﬁts of AIDS treatment in the United States. J Infect Dis, 194:11–9. Westby M, Lewis M, Whitcomb J, et al. 2006. Emergence of CXCR4-using human immunodeﬁciency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol, 80:4909–20. Westby M, Smith-Burchnell C, Mori J, et al. 2007. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol, 81:2359–71. Wilkin TJ, Su Z, Kuritzkes DR, et al. 2007. HIV type 1 chemokine core- ceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. J Infect Dis, 44:591–5. Wong MM, Fish EN. 2003. Chemokines: attractive mediators of the immune response. Semin Immunol, 15:5–14. Wood A, Armour D. 2005. The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS. Prog Med Chem, 43:239–71. Zhao J, Ma L, Wu YL, et al. 1998. Chemokine receptor CCR5 functionally couples to inhibitory G proteins and undergoes desensitization. J Cell Biochem, 71:36–45. Therapeutics and Clinical Risk Management 2008:4(2) 485